C3L-02164
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 58.18480493
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- TNFA_SIGNALING_VIA_NFKB+0.550
- IL6_JAK_STAT3_SIGNALING+0.520
- ALLOGRAFT_REJECTION+0.510
- INFLAMMATORY_RESPONSE+0.460
- IL2_STAT5_SIGNALING+0.430
- ANGIOGENESIS+0.420
- COAGULATION+0.410
- COMPLEMENT+0.390
- MYOGENESIS+0.360
Top 10 suppressed
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V1-0.490
- PROTEIN_SECRETION-0.380
- MYC_TARGETS_V2-0.370
- GLYCOLYSIS-0.330
- OXIDATIVE_PHOSPHORYLATION-0.310
- MTORC1_SIGNALING-0.290
- DNA_REPAIR-0.280
- MITOTIC_SPINDLE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0EP-01A-52R-A22U-07 | — | A | 0.946 |
| 2 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.944 |
| 3 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.943 |
| 4 | C3L-02170 | — | cohortMD2 | 0.937 |
| 5 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.932 |
| 6 | TCGA-L9-A743-01A-43R-A39D-07 | — | cohortA1 | 0.924 |
| 7 | ERR2598314 | fetal | fetal | 0.924 |
| 8 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.923 |
| 9 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.923 |
| 10 | R304 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |